2026-11-05

Nine-Time Honoree: CMS Named “Honored Company” by Extel, and Ms. Chen Yanling Awarded “Best CFO”

On November 5, the Asia Equities Awards Ceremony hosted by Extel (formerly known as “Institutional Investor”), an authoritative international financial magazine, was held in Hong Kong. China Medical System Holdings Limited (“CMS” or the “Group”) stood out among more than 1,000 participating companies and was recognized as an “Honored Company” of the “2026 Asia Executive Team” rankings in the biopharmaceuticals sector (Small & Mid Cap). Ms. Chen Yanling, the Group’s Executive Director, Chief Financial Officer and Vice President, ranked first overall for “Best CFO”  in the sector. This marks the Group’s ninth appearance in the rankings.   Extel is one of the professional capital market research and ranking institutions with broad influence in global capital markets. Its annual “Best Executive Team” rankings are an important benchmark for the international investment community to measure the management and investor relations performance of listed companies. This year’s survey gathered evaluations from 5,581 buy-side and sell-side professionals from 1,249 financial institutions. These honors reflect capital markets’ strong recognition of CMS’s corporate governance, investor […]

2026-11-10

CMS Honored with the 2026 Stock Star Capital Power “Outstanding Listed Company Award”

On November 6, 2026, at the 14th “Capital Power” annual brand event hosted by Stock Star, CMS was honored with the “Outstanding Listed Company Award” in recognition of its outstanding performance in differentiated innovation strategy, solid operating results, and corporate governance. Since its launch in 2012, Stock Star’s “Capital Power” annual brand event has been held for 14 consecutive editions, dedicated to identifying outstanding companies in the capital market and providing evaluation and benchmarks for the development of the financial industry and listed companies. The “Outstanding Listed Company Award” focuses on assessing a company’s products and technologies competitiveness, value creation capability, operating resilience, investment in innovative R&D, and corporate governance standards. This award underscores the capital market’s full recognition of CMS’s overall strength, innovation achievements, and sound governance. CMS has been deeply engaged in the pharmaceutical industry for more than 30 years, focusing on the identification, building, and full lifecycle management of differentiated […]

2026-11-04

CMS: Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment

Ruxolitinib phosphate cream is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo. It is also the first drug specifically for repigmentation in non-segmental vitiligo, filling a decades-long void in the field and offering new hope for patients.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Rxilient Medical received approval from the Health Sciences Authority of Singapore (HSA) on 3 November 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product” or “Lumirix®”) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. It is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo[1], meeting a long-standing unmet clinical need. This approval fills a gap in the field of vitiligo treatment in Singapore. In addition to Singapore, Rxilient Medical has already launched sales of […]

2026-09-14

China Medical System’s Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Systemic Lupus Erythematosus

CMS-D001 is an oral highly selective TYK2 inhibitor. Compared with pan-JAK inhibitors, it has less impact on other JAK family kinases,and, is expected to lower safety risks while maintaining efficacy. Compared with marketed injectable biologics, it offers the advantages of oral administration and no risk of anti-drug antibody formation, providing potential treatment convenience for patients.   If approved, CMS-D001 will provide a new treatment option for patients with SLE in Chinaand create strong synergies with innovative drugs such as Metoject, further enhancing the Group’s competitiveness in the field of autoimmune diseases.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, on 11 September 2026, the innovative drug CMS-D001 Tablets (“CMS-D001” or the “Product”) has been granted the Drug Clinical Trial Approval Notice by the National Medical Products Administration of the People’s Republic of China (“NMPA”). The approval notice was obtained on 14 September 2026. The NMPA grants consent to conduct clinical trials evaluating the safety and efficacy […]

2026-09-09

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China, Accelerating Clinical Application

On 9 September, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China.   Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, […]

2026-09-03

CMS Charity | Supporting Each Other Through Adversity: CMS Donated RMB 1 Million to Support Debris-Flow-Hit Area in Gyirong, Tibet

On 26 August 2026, a large-scale ice-rock avalanche in Nepal triggered a debris flow that struck Gyirong Port in Gyirong County, Shigatse, Tibet, resulting in significant casualties, missing persons and infrastructure damage. The sudden disaster has drawn widespread concern for the safety and well-being of those affected. In response, China Medical System Holdings Limited (CMS) acted swiftly to support emergency relief and recovery efforts, donating RMB 1 million in cash through the Tibet Autonomous Region Charity Federation to the disaster-affected areas of Gyirong County, Shigatse, Tibet. The donation will support emergency rescue operations, resettlement for affected residents and post-disaster reconstruction, providing tangible support to frontline responders and the basic living needs of the affected population. The pharmaceutical industry was born out of the need to save lives, and it gains its humanity through its commitment to protecting them. Guided by its founding commitment to “fulfill social responsibility and safeguard life and health,” CMS […]

CMS: Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)

Second indication approved: As the first topical JAK inhibitor approved in China for the treatment of vitiligo, Lumirix®has received China approval for the additional indication of atopic dermatitis (AD), offering a novel treatment option for pediatric patients 2 years of age and older, adolescent and adult AD patients, with safety and efficacy supported by clinical data*.  Impressive Phase III AD data in China: At week 8, 63.0% of subjects achieved IGAof 0 or 1 with at least two grades of reduction from baseline, versus 9.2% for placebo; 78.0% of subjects achieved EASI 75, versus 15.4% for placebo. A comprehensive AD “treatment + care” solution: Dermavon has developeda professional AD treatment-and-care portfolio comprising Lumirix® (topical formulation, mild-to-moderate AD), Comekibart Injection (injectable biological agent, moderate-to-severe AD), CMS-D001 (oral small molecule targeted drug, moderate-to-severe AD), and the Heling Soothing Product Series (daily repair).   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce […]

2026-08-11

Secretary of the CPC Hainan Provincial Committee Feng Fei Visits Dermavon Hainan

On August 10, 2026, Mr. Feng Fei, Secretary of the Hainan Provincial Committee of the Communist Party of China (CPC), headed a delegation for an inspection tour of Dermavon Hainan, a skin health subsidiary of China Medical System. The delegation conducted an on-site review of the company’s development, innovative R&D, and construction progress of Hainan R&D and Manufacturing Base. The inspection tour was accompanied by Fan Shaojun, Member of the Standing Committee of the Hainan Provincial Committee and Secretary of the Haikou Municipal Committee; Zhang Yong, Mayor of Haikou; Yang Zhongcheng, Director-general of the Policy Research Office of the Hainan Provincial Committee; Qi Shuli, Director of the Hainan Development and Reform Commission; Ji Tiejun, Director of the Hainan Medical Products Administration; Wang Yuan, Deputy Director-General of the Hainan Provincial Department of Industry and Information Technology. During the inspection, Huang Anjun, Executive Director and CEO of Dermavon, gave a briefing to Secretary Feng and the accompanying delegation on the Company’s […]

2026-07-27

CMS: Rxilient Obtained Commercialization Rights for Dermatology Improved New Drug Finjuve and Branded Drug Ciclopoli in Southeast Asia and Other Markets

Finjuve, animproved new drug, is the first and only topical finasteride product worldwide approved for the treatment of androgenetic alopecia. Its efficacy is comparable to oral finasteride, while showing 100-fold lower systemic exposure and less impact on serum DHT levels compared with oral finasteride, offering an effective hair-loss treatment option with lower risk. Ciclopoli, a branded drug, uses patented HPCH water-soluble transungual technology. It does not require nail filing or organic solvents to remove the film, combining strong efficacy, safety, and convenience, and offering a superior topical treatment option for onychomycosis patients. Leveraging itsestablished registration and commercialization capabilities across Southeast Asia, Rxilient will accelerate the launch of both products, injecting new momentum into business growth in the region.   Recently, the Southeast Asia business subsidiary of China Medical System (“CMS”), Rxilient Medical Pte. Ltd. (“Rxilient”), entered into a partnership with Polichem S.A., a subsidiary of Almirall S.A. (ALM), a global biopharmaceutical company focused on medical dermatology. Rxilient obtained […]

2026-07-17

Dual ESG Recognition: CMS Named Among “China ESG Leaders 2026” and Honored with the “Green Supply Chain Leadership Award”

Recently, SynTao Green Finance officially released the Steady Progress for a Sustainable Future: China ESG Leaders Annual Report 2026. China Medical System Holdings Limited (“CMS” or “the Group”) was successfully named among “China ESG Leaders 2026”, recognized for its long-term dedication and outstanding practices in the Environmental, Social, and Governance (ESG) fields. Additionally, CMS was honored with the “Green Supply Chain Leadership Award” in the ESG selection hosted by Stockstar. This double recognition underscores the strong affirmation from professional institutions and the market for the Group’s sustainable development initiatives. Published by SynTao Green Finance, a leading ESG rating agency in China, the Steady Progress for a Sustainable Future: China ESG Leaders Annual Report 2026 is widely recognized for its high credibility and influence. Stockstar’s “ESG New Benchmark Awards”, themed “Innovation, Co-governance, Long-term Value”, introduced the “Green Supply Chain Leadership Award” for the first time. The award specifically focuses on corporate practices and achievements in building green, low-carbon, and responsible supply chains. As […]

2026-07-15

China Medical System: Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is Approved for Drug Clinical Trials for Age-related Macular Degeneration

CMS-D017 is a novel selective small-molecule inhibitor of complement factor B (CFB). Through administered orally, targeting and inhibiting complement factor B,it blocks abnormal activation of the alternative complement pathway, and thereby slows the progression of complement dysregulation-related diseases such as age-related macular degeneration (“AMD”), offering a potentially superior and more convenient treatment option[1]. CMS-D017 has demonstrated favourable efficacy and safety profiles in preclinical studies. Upon approval for marketing, CMS-D017 will synergise with the marketed innovative drug Beovu®(diabetic macular oedema, etc.), the branded drug Lucentis® (neovascular age-related macular degeneration, etc.), and the exclusive drug Augentropfen Stulln Mono Eye Drops (senile macular degeneration and all forms of asthenopia), building a multi-layered, precise and comprehensive solution for ophthalmic diseases.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 15 July 2026, the Group’s self-developed innovative drug, Complement Factor B inhibitor CMS-D017 capsules (“CMS-D017” or the “Product”), obtained the Drug Clinical Trial Approval Notice […]